TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03826381

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance (MR) spectroscopy of the liver
Description: Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance (MR) spectroscopy of the liver
Description: Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Transient Elastography for Measurement of liver fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Transient Elastography for Measurement of liver fibrosis.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM) for four days.
Description: CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM) for four days.
Description: CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.

Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry (DEXA) scan
Description: DEXA-scan of the body composition.

Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry (DEXA) scan
Description: DEXA-scan of the body composition.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.

Intervention type: OTHER
Intervention: Clinical and demographic data
Description: Measurements of blood pressure, pulse, height, weight.

Intervention type: OTHER
Intervention: Clinical and demographic data
Description: Measurements of blood pressure, pulse, height, weight.
Study: NCT00692926

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALDHbr Umbilical Cord Blood Cells
Description: ALDHbr sorted Umbilical Cord Blood Cells

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALDHbr Umbilical Cord Blood Cells
Description: ALDHbr sorted Umbilical Cord Blood Cells

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALDHbr Umbilical Cord Blood Cells
Description: ALDHbr sorted Umbilical Cord Blood Cells

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALDHbr Umbilical Cord Blood Cells
Description: ALDHbr sorted Umbilical Cord Blood Cells
Study: NCT00152321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patients (education, counseling) and Physicians (reminders,1-page guidelines).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: Educational materials, counseling, opinion leader based guidelines, reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT04066179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gcsf
Description: Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gcsf
Description: Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 40 mg for initial 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 40 mg for initial 7 days
Study: NCT03191721

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical anti-infective therapy
Description: Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical anti-infective therapy
Description: Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
Study: NCT01168492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.5mg/kg ketamine iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ketamine
Description: 0.5mg/kg ketamine iv
Study: NCT02724943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI screening
Description: Physician screening of patients to identify patients who are overweight or obese.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI screening
Description: Physician screening of patients to identify patients who are overweight or obese.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Next Steps brief clinical intervention
Description: This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Next Steps brief clinical intervention
Description: This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEND/CATCH
Description: MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEND/CATCH Transition Phase
Description: The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Next Steps Self-Paced Booklet
Description: Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
Study: NCT01087008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment control
Description: Patients doesn't receive treatment
Study: NCT03234426

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perturbation
Description: Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
Study: NCT00402688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: 750mg tablet once daily for 3 weeks followed by 1 week of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: 500mg tablet once daily for 4 weeks.
Study: NCT01427647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic technique and thoracic epidural anesthesia
Description: We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic technique and thoracic epidural anesthesia
Description: We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
Study: NCT03027570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame activity_EXG
Description: In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application activity
Description: The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity.
Study: NCT00767325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
Study: NCT01427647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic technique and thoracic epidural anesthesia
Description: We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
Study: NCT02084043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
Study: NCT00767325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
Study: NCT03982758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric handgrip exercise
Description: Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric of the lower limbs
Description: Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
Study: NCT01983956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENS model
Description: Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
Study: NCT03234426

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physiotherapy Treatment
Description: Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy Treatment
Description: Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
Study: NCT02084043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
Description: 500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
Study: NCT04879186

Intervention type: PROCEDURE
Intervention: Peripheral endovascular angioplasty
Description: Peripheral endovascular angioplasty - using endovascular techniques to treat peripheral artery occlusive lesions.
Study: NCT05333302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T-cells
Description: One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
Study: NCT04572503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbed Suture Modified Anterior Palatoplasty
Description: Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
Study: NCT00679939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: up to 8mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 2000mg/day
Study: NCT00688818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
Study: NCT03292250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Initial dose 200 mg twice per day orally according to study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab,Tremelimumab
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study: NCT01284348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 15 mg
Description: Sotatercept 15 mg SC injection once every 42 days, up to four doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept 30 mg
Description: Sotatercept 30 mg SC injection once every 42 days, up to four doses
Study: NCT02991781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback and Neurofeedback Training
Description: The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback and Neurofeedback Training
Description: The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
Study: NCT04559100

Intervention type: RADIATION
Intervention: chest radiography
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
Study: NCT03389230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2(EQ)BBζ/CD19t+ T cells
Description: Given via catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2(EQ)BBζ/CD19t+ T cells
Description: Given via catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2(EQ)BBζ/CD19t+ T cells
Description: Given via catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study: NCT04559100

Intervention type: RADIATION
Intervention: thoracic computed tomography scan
Description: 6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusing capacity of carbon monoxide
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: 6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: saint george respiratory questionnaire
Description: 6 and 12 months after hospital discharge.
Study: NCT02209519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole (male partner)
Description: 500 mg PO BID for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placeob (male partner)
Description: matching placebo capsules PO BID for 7 days
Study: NCT02329379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study: NCT03389230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study: NCT02991781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback and Neurofeedback Training
Description: The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.